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Abstract
Background: Tissue Doppler imaging (TDI) is a noninvasive echocardiographic method for the diagnosis of
diastolic dysfunction in patients with varying degrees of aortic stenosis (AS). Little is known however, on the utility
of TDI in the serial assessment of diastolic abnormalities in AS.
Objective: The aim of the current proposal was to examine whether treatment with rosuvastatin was successful in
improving diastolic abnormalities in patients enrolled in the Aortic Stenosis Progression Observation Measuring
Effects of Rosuvastatin (ASTRONOMER) study.
Methods: Conventional Doppler indices including peak early (E) and late (A) transmitral velocities, and E/A ratio
were measured from spectral Doppler. Tissue Doppler measurements including early (E’) and late (A’) velocities of
the lateral annulus were determined, and E/E’ was calculated.
Results: The study population included 168 patients (56 ± 13 years), whose AS severity was categorized based on
peak velocity at baseline (Group I: 2.5-3.0 m/s; Group II: 3.1-3.5 m/s; Group III: 3.6-4.0 m/s). Baseline and follow-up
hemodynamics, LV dimensions and diastolic functional parameters were evaluated in all three groups. There was
increased diastolic dysfunction from baseline to follow-up in each of the placebo and rosuvastatin groups. In
patients with increasing severity of AS in Groups I and II, the lateral E’ was lower and the E/E’ (as an estimate of
increased left ventricular end-diastolic pressure) was higher at baseline (p < 0.05). However, treatment with
rosuvastatin did not affect the progression of diastolic dysfunction from baseline to 3.5 year follow-up between
patients in any of the three predefined groups.
Conclusion: In patients with mild to moderate asymptomatic AS, rosuvastatin did not attenuate the progression of
diastolic dysfunction.
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Aortic stenosis (AS) is the most common valvular heart
disease in adult subjects in North America [1,2]. It causes
fixed left ventricular (LV) outflow tract obstruction, lead-
ing to concentric left ventricular hypertrophy (LVH) and
diastolic dysfunction [2,3]. Diastolic dysfunction is char-
acterized by an increased resistance to filling due to
increased LV mass, resulting in increased LV end diasto-
lic pressures [2,4]. The inability of the myocardium to
relax compromises passive filling of the LV, leading to
angina, dyspnea, and pulmonary congestion [2,4].
Tissue Doppler imaging (TDI) is recognized as a non-
invasive tool to determine abnormal LV relaxation, and
has been shown to be effective in analyzing left ventri-
cular diastolic function in relation to mitral annulus
velocity [5-7]. In patients with varying degrees of AS
severity, TDI is effective in evaluating diastolic dysfunc-
tion [8-12]. TDI has been shown to be effective in evalu-
ating subtle changes in diastolic properties of the heart,
even in the absence of LVH [8]. Little is known how-
ever, on the utility of TDI in the serial assessment of
diastolic abnormalities in patients with AS.
T h ea i mo ft h ec u r r e n ts t u d yw a st oe x a m i n e
whether treatment with rosuvastatin was successful in




Between 2002-2005, 272 patients from 23 Canadian cen-
ters with mild to moderate AS were recruited for the Aor-
tic Stenosis Progression Observation Measuring Effects of
Rosuvastatin study (ASTRONOMER), a multicenter ran-
domized trial to evaluate the effects of rosuvastatin on the
progression of AS [13]. Patients between the ages of 18
and 82 years with mild to moderate AS, defined by a peak
Doppler aortic valve velocity of 2.5 to 4.0 m/s, were
included. Subjects were divided into three predefined cate-
gories of AS severity (peak velocity 2.5-3.0 m/s; 3.1-3.5 m/s;
and 3.6-4.0 m/s). The baseline low-density lipoprotein
cholesterol complex and triglyceride levels needed to be
within target level for all risk categories according to the
Canadian Guidelines for patients to be included in the
trial [14]. Patients were excluded if they had a very high
risk of coronary artery disease (CAD) with an estimated
10 year risk exceeding 30% risk, preexisting diabetes,
known CAD, congestive heart failure with New York
Heart Association class III or IV symptoms, uncontrolled
hypertension (defined as diastolic blood pressure
>100 mm Hg or systolic blood pressure > 200 mm Hg),
atrial fibrillation or bradyarrhythmias, greater than mod-
erate aortic regurgitation, significant concomitant mitral
valve disease, or significant renal impairment (serum
creatinine > 200 umol/L) [13]. After the baseline assess-
ment and randomization, the patients were followed up
every 3 months to assess for adverse side effects and to
ensure compliance. For patients undergoing aortic valve
replacement, the measurements on the last echocardio-
grams before surgery were used in the analysis [13].
For the purpose of the current subanalysis of the
ASTRONOMER study, only those individuals with com-
plete and analyzable diastolic echocardiographic para-
meters at the culmination of the study were included.
The final cohort included 168 patients in whom diasto-
lic echocardiographic parameters were available both at
baseline and at study end. The study protocol was
approved by the institutional review boards at the var-
ious participating centers.
Echocardiography
Parasternal and apical views were obtained using standard
echocardiographic systems and multifrequency transducers
with tissue Doppler capability. Standard two-dimensional
images, M-mode, spectral and color Doppler, and TDI
were performed. LV interventricular septal thickness, pos-
terior wall thickness, and LV ejection fraction were deter-
mined from two-dimensional images according to
established criteria [15]. LV mass was calculated using the
cube formula and indexed to body surface area [15]. Heart
rate, SBP and DBP were recorded at the time of echo.
Transmitral LV filling velocities at the tips of the
mitral valve leaflets were obtained from the apical four-
chamber view using pulsed-wave Doppler echocardio-
graphy. The transmitral LV filling signal was traced
manually, and the following variables were obtained:
peak early (E) and late (A) transmitral velocities, E/A
ratio, and E-wave deceleration time. Tissue Doppler-
derived indices were recorded at the lateral mitral annu-
lus. These indices included systolic velocities (S’), early
diastolic velocities (E’), and late diastolic velocities (A’).
Finally, the dimensionless index of E/E’ was calculated.
Statistics
The data is summarized as mean ± standard deviation
or number (%). Within each arm, placebo and rosuvas-
tatin respectively, baseline and follow-up values were
compared using two-sample t-test. To compare changes
in the clinical and echocardiographic variables between
the two arms (placebo vs. rosuvastatin), all follow-up
values were averaged, subtracted from baseline measure-
ments, and the changes were compared using a two-
sample t-test or Wilcoxon rank test depending on the
distribution of the change. A p value less than 0.05 was
considered statistically significant. The Statistical Analy-
sis System 8.01 (SAS Institute, Cary, NC), was used to
perform the analysis.
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[92 males (55%)] with a mean age of 56 ± 13 years, who
fulfilled the echocardiographic criteria. The patients were
divided into three predetermined categories of AS severity
based on peak velocity at baseline (Group I: 2.5-3.0 m/s;
Group II: 3.1-3.5 m/s; Group III: 3.6-4.0 m/s). Baseline
and follow-up hemodynamics, LV dimensions and diasto-
lic functional parameters were independently evaluated in
all three groups.
Baseline and follow-up data comparing the placebo arm
to the treatment arm for Group I (2.5-3.0 m/s) are shown
in Table 1. Heart rate, systolic and diastolic blood pres-
sures were similar from baseline to follow-up. The severity
of AS increased from a peak gradient of 31 ± 3 mm Hg to
42 ± 11 mm Hg in the placebo arm, and 32 ± 3 mm Hg to
43 ± 12 mm Hg in the rosuvastatin arm (p < 0.05 for each
arm, respectively). However, the mean difference in pro-
gression of AS severity from baseline and follow-up
between both arms did not differ (p = 0.60) (Table 1).
All 64 patients in group I had conventional and TDI
diastolic parameters assessed at baseline and 3.5 year
follow-up (Table 1). There was no difference in mean
transmitral E-wave, A-wave, nor E/A ratio between both
Table 1 Clinical and echocardiographic findings of Group I patients (n = 64) in the two treatment groups
Characteristics Placebo (n = 37) Rosuvastatin (n = 27) p value
Baseline Follow-up Baseline Follow-up
Age, y 56 ± 13 51 ± 11 0.17
Hemodynamics
HR (bpm) 70 ± 8 70 ± 11 70 ± 8 68 ± 10 0.82
SBP (mm Hg) 130 ± 17 131 ± 13 131 ± 20 132 ± 17 0.76
DBP (mm Hg) 77 ± 10 77 ± 13 76 ± 9 74 ± 11 0.79
Aortic Valve Parameters
AVA (cm
2) 1.9 ± 0.7 1.6 ± 0.7* 1.9 ± 0.6 1.6 ± 0.6† 0.62
AV peak velocity (m/s) 2.8 ± 0.1 3.3 ± 0.7* 2.7 ± 0.2 3.1 ± 0.5† 0.57
AV peak gradient (mm Hg) 31 ± 3 42 ± 11* 32 ± 3 43 ± 12† 0.60
AV mean gradient (mm Hg) 17 ± 2 31 ± 3* 17 ± 2 30 ± 4† 0.58
Left Heart Dimensions
IVS (mm) 11 ± 2 11 ± 2 11 ± 2 11 ± 2 0.94
PWT (mm) 10 ± 2 11 ± 2 10 ± 2 10 ± 2 0.76
LA (mm) 37 ± 6 37 ± 6 36 ± 6 37 ± 7 0.78
LVEDD (mm) 49 ± 5 49 ± 7 49 ± 7 49 ± 7 0.81
LVESD (mm) 29 ± 4 29 ± 7 29 ± 6 29 ± 6 0.84
LV mass/BSA (g/m
2)
Men 95 ± 24 93 ± 23 94 ± 28 95 ± 23 0.61
Women 85 ± 19 87 ± 25 84 ± 24 86 ± 19 0.69
EF (%) 65 ± 6 67 ± 4 65 ± 6 68 ± 9 0.58
Conventional Diastolic Parameters
Mitral E velocity (cm/sec) 84 ± 19 88 ± 23 82 ± 20 89 ± 21 0.59
Mitral A velocity (cm/sec) 74 ± 18 76 ± 18 73 ± 25 75 ± 25 0.64
E/A ratio 1.2 ± 0.4 1.1 ± 0.3 1.1 ± 0.4 1.2 ± 0.5 0.71
Tissue Doppler Imaging
Lateral S’ 8.4 ± 3.2 8.3 ± 1.8 8.5 ± 2.3 8.4 ± 2.1 0.75
Lateral E’ 10.2 ± 4.2 8.0 ± 3.2* 10.5 ± 3.5 8.2 ± 3.1† 0.66
Lateral A’ 9.2 ± 3.6 9.4 ± 2.8 9.1 ± 2.4 9.4 ± 3.0 0.56
E/E’ (lateral) 8 ± 4 11 ± 3* 8 ± 3 11 ± 4† 0.43
Values are mean ± SD (percentage). y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute; AVA, aortic valve
area; AV, aortic valve; IVS, interventricular septum; PWT, posterior wall thickness; LA; left atrium diameter in anterior-posterior dimension; LVEDD, left ventricular
end diastolic diameter; LVESD, left ventricular end systolic diameter; LV, left ventricular; BSA, body surface area; EF, ejection fraction; S’, systolic annular velocity;
E’, early diastolic annular velocity; A’, late diastolic annular velocity. p < 0.05* was considered significant comparing baseline and follow-up values within the
placebo arm. p < 0.05† was considered significant comparing baseline and follow-up values within the rosuvastatin arm. Overall p values are listed for the
difference of baseline and follow-up measurements comparing placebo vs. rosuvastatin, with p < 0.05‡ considered significant.
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± 4.2 cm/s to 8.0 ± 3.2 cm/s in the placebo arm, and
10.5 ± 3.5 cm/s to 8.2 ± 3.1 cm/s in the rosuvastatin
arm (p < 0.05 for each arm, respectively), as shown in
Figure 1. The lateral E/E’ increased from approximately
8 to 11 over time in both placebo and rosuvastatin arms
(p < 0.05), respectively. However, there was no differ-
ence in progression of diastolic dysfunction from base-
line to follow-up at 3.5 years, comparing placebo vs.
rosuvastatin (p = 0.43) (Table 1).
In Group II (3.1-3.5 m/s), the peak AS gradient
increased from 41 ± 4 mm Hg to 62 ± 23 mm Hg in
the placebo arm, and 42 ± 4 mm Hg to 59 ± 14 mm Hg
in the rosuvastatin arm (p < 0.05 for each arm, respec-
tively), as shown in Table 2. Although the severity of AS
increased to the moderate range within each arm, there
was no difference in the degree of progression of AS
a m o n g s tb o t hg r o u p s( p=0 . 3 5 ) .A l l6 3p a t i e n t si n
group II had conventional and TDI diastolic parameters
assessed at baseline and follow-up (Table 2). There was
no statistical difference in conventional measures of dia-
stolic function between both arms. Although the lateral
E/E’ increased from 11 to 15 over time within each arm
(p < 0.05), respectively, there was no difference in pro-
gression from baseline to follow-up at 3.5 years compar-
ing placebo vs. rosuvastatin in Group II (p = 0.62)
(Table 2).
In Group III (3.6-4.0 m/s), the peak AS gradient
increased from 56 ± 4 mm Hg to 80 ± 19 mm Hg in
the placebo arm, and 56 ± 4 mm Hg to 79 ± 16 mm Hg
in the rosuvastatin arm (p < 0.05 for each arm, respec-
tively). There was no difference in progression of AS
from moderate to severe amongst both groups (p =
0.85), as shown in Table 3. Of the 41 patients in group
III who had conventional and TDI diastolic parameters
assessed at baseline and follow-up, the conventional dia-
stolic parameters were similar. Although the lateral E/E’
was elevated at baseline in both groups, there was no
significant increase identified over the follow-up of 3.5
years (Table 3).
Discussion
In this observational sub-study from the ASTRONO-
MER trial, we sought to determine whether statin ther-
apy improved diastolic dysfunction in patients with mild
to moderate AS after a median follow-up of 3.5 years.
There was increased diastolic dysfunction from baseline
to follow-up in each of the placebo and rosuvastatin
arms. In patients with increasing severity of AS in
groups I and II, the lateral E’ decreased and the E/E’
increased over time within each arm, despite no change
in LV mass nor LVEF (p < 0.05). However, there was no
difference in progression of diastolic dysfunction from
baseline to follow-up between patients in all three pre-
defined groups with AS who received placebo versus
rosuvastatin. To the best of our knowledge, this is the
first clinical investigation that specifically examined the
effects of statins on the progression of diastolic dysfunc-
tion in patients with AS.
From a pathophysiologic perspective, the obstruction
imposed on the LV from the stenotic AV produces sys-
tolic wall stress, which in turn leads to concentric LVH
[2-4]. Although the increased LV mass may help in
maintaining overall systolic function, an impairment in
diastolic function arises [2-4]. The spectrum of diastolic
abnormalities include increased myocardial stiffness,
reduced LV compliance, and elevated left atrial and LV
end-diastolic pressures [2-4]. These diastolic abnormal-
ities eventually lead to the clinical manifestations of
angina, dyspnea, and pulmonary congestion [2-4].
It has been suggested that statins may have beneficial
effects on diastolic parameters, predominantly by
attenuating the degree of LVH and cardiac fibrosis in
murine models of hypertension [16,17]. Indolfi et al.
examined the effect of simvastatin on chronic pressure-
overloaded left ventricles in Wistar rats [16]. The
administration of simvastatin significantly reduced renin
angiotensin system (RAS) membrane targeting, RAS in
vivo activation, and ERK2 phosphorylation, which pre-
vented the development of LVH in this murine model
of chronic pressure overload. Similarily, Luo et al.
demonstrated that simvastatin reduced LVH due to
inhibition of local cardiac angiotensin converting
enzyme (ACE) activity [17].
A number of clinical studies have evaluated diastolic
dysfunction in patients with varying degrees of AS
severity [8-12]. We previously demonstrated that in
patients with mild to moderate AS (AVA 1.2-1.7 cm
2),
Figure 1 Diastolic parameters in Group I. Representative diastolic
and TDI parameters at baseline and follow-up in either placebo or
rosuvastatin treated groups, demonstrating no change in E/A ratio,
but a decrease in the lateral E’.
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related to increasing severity of AS [8]. Specifically, the
lateral E’ was lower and the E/E’ was higher with greater
severity of AS [8]. Diastolic abnormalities in a subset of
patients with asymptomatic moderate AS were recently
examined in the Simvastatin and Ezetimibe in Aortic
Stenosis (SEAS) baseline population [9]. The severity of
AS in this patient population was defined as an aortic
valve area of 1.2 ± 0.4 cm
2 and a mean transaortic peak
velocity of 3.2 ± 0.5 cm/s [9]. The LV diastolic function
was impaired as evident from augment LV filling pres-
sures (measured by septal E/E’ and E/Vp) and impaired
LV relaxation (measured by reduced septal E’)[ 9 ] .Lan-
celotti et al. evaluated patients with severe AS (AVA
0.8-0.2 cm
2;m e a ng r a d i e n t4 5m mH g ) ,i nw h o ma n
E/E’ ratio >14 identified a subset of patients at greater
risk of future events [11]. Finally, Bruch et al. demon-
strated an impairment in diastolic function using TDI in
symptomatic patients with advanced aortic AS and LVH
[12]. In this small, single centre study, 36 patients with
moderate to severe AS were evaluated with a mean
AVA of 0.8 ± 0.4 cm
2 and mean transaortic pressure
gradient of 57 ± 17 mm Hg [12]. Bruch et al. demon-
s t r a t e dt h a tt h eE / E ’ ratio allows for a reliable and
Table 2 Clinical and echocardiographic findings of Group II patients (n = 63) in the two treatment groups
Characteristics Placebo (n = 27) Rosuvastatin (n = 36) p value
Baseline Followup Baseline Followup
Age, y 56 ± 12 59 ± 14 0.38
Hemodynamics
HR (bpm) 68 ± 8 69 ± 12 72 ± 9 71 ± 10 0.54
SBP (mm Hg) 130 ± 17 128 ± 11 130 ± 14 130 ± 15 0.81
DBP (mm Hg) 77 ± 11 74 ± 11 77 ± 11 75 ± 9 0.41
Aortic Valve Parameters
AVA (cm
2) 1.5 ± 0.5 1.1 ± 0.3* 1.5 ± 0.4 1.1 ± 0.4† 0.58
AV peak velocity (m/s) 3.2 ± 0.1 3.9 ± 0.7* 3.2 ± 0.1 3.8 ± 0.5† 0.64
AV peak gradient (mm Hg) 41 ± 4 62 ± 23* 42 ± 4 59 ± 14† 0.35
AV mean gradient (mm Hg) 22 ± 4 35 ± 13* 23 ± 3 34 ± 9† 0.63
Left Heart Dimensions
IVS (mm) 11 ± 2 11 ± 2 11 ± 2 11 ± 2 0.95
PWT (mm) 10 ± 1 11 ± 2 11 ± 1 11 ± 2 0.56
LA (mm) 36 ± 6 37 ± 7 39 ± 7 39 ± 7 0.42
LVEDD (mm) 48 ± 6 47 ± 5 48 ± 6 47 ± 6 0.92
LVESD (mm) 29 ± 5 27 ± 5 28 ± 5 27 ± 6 0.36
LV mass/BSA (g/m
2)
Men 93 ± 22 94 ± 20 93 ± 24 96 ± 17 0.51
Women 82 ± 17 84 ± 19 81 ± 14 83 ± 19 0.72
EF (%) 66 ± 5 66 ± 6 68 ± 6 68 ± 7 0.89
Conventional Diastolic Parameters
Mitral E velocity (cm/sec) 80 ± 15 81 ± 22 81 ± 22 80 ± 27 0.64
Mitral A velocity (cm/sec) 80 ± 27 78 ± 22 80 ± 27 79 ± 28 0.82
E/A ratio 1.0 ± 0.3 1.1 ± 0.2 1.0 ± 0.3 1.0 ± 0.3 0.65
Tissue Doppler Imaging
Lateral S’ 8.1 ± 1.9 8.1 ± 1.6 8.2 ± 1.8 8.3 ± 2.2 0.72
Lateral E’ 7.0 ± 1.2 6.0 ± 2.1* 7.1 ± 3.2 6.1 ± 2.6† 0.66
Lateral A’ 10.1 ± 3.1 9.4 ± 3.5 10.6 ± 3.6 10.3 ± 2.3 0.55
E/E’ (lateral) 11 ± 4 15 ± 3* 11 ± 3 15 ± 4† 0.62
Values are mean ± SD (percentage). y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute; AVA, aortic valve
area; AV, aortic valve; IVS, interventricular septum; PWT, posterior wall thickness; LA; left atrium diameter in anterior-posterior dimension; LVEDD, left ventricular
end diastolic diameter; LVESD, left ventricular end systolic diameter; LV, left ventricular; BSA, body surface area; EF, ejection fraction; S’, systolic annular velocity;
E’, early diastolic annular velocity; A’, late diastolic annular velocity. p < 0.05* was considered significant comparing baseline and follow-up values within the
placebo arm. p < 0.05† was considered significant comparing baseline and follow-up values within the rosuvastatin arm. Overall p values are listed for the
difference of baseline and follow-up measurements comparing placebo vs. rosuvastatin, with p < 0.05‡ considered significant.
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patients with advanced AS, as compared to age-matched
controls [12].
Despite the lack of clinical studies examining the effect
of statins on preventing diastolic dysfunction in AS
patients, a study by Fukuta et al. suggested that statin
therapy may lower mortality in patients with diastolic
heart failure due to its pleotropic effects in hypertension
and CAD [18]. In this non-randomized and non-blinded
study involving 137 patients followed for a mean of
21 months, 34 patients with statin therapy were alive at
study termination compared with 26 in the placebo
group (p = 0.003) [18]. Statin therapy also led to a trend
in decreased cardiovascular hospitalizations (p = 0.08)
[18]. The findings of this study were clearly hypothesis-
generating.
T h er e s u l t so fo u rs t u d ya r eu n i q u ei nt h a ti ti st h e
first to directly evaluate the effects of statins on prevent-
ing the progression of diastolic dysfunction in patients
with AS. With increasing severity of AS, the degree of
diastolic dysfunction, as reflected by a lower E’ and
higher E/E’ ratio, is in agreement with previous studies
Table 3 Clinical and echocardiographic findings of Group III patients (n = 41) in the two treatment groups
Characteristics Placebo (n = 21) Rosuvastatin (n = 20) p value
Baseline Followup Baseline Followup
Age, y 58 ± 11 53 ± 16 0.22
Hemodynamics
HR (bpm) 74 ± 11 72 ± 12 71 ± 10 70 ± 7 0.38
SBP (mm Hg) 129 ± 16 127 ± 14 133 ± 15 130 ± 14 0.54
DBP (mm Hg) 80 ± 9 77 ± 10 78 ± 10 76 ± 7 0.62
Aortic Valve Parameters
AVA (cm
2) 1.2 ± 0.4 1.1 ± 0.6 1.3 ± 0.5 1.1 ± 0.5 0.67
AV peak velocity (m/s) 3.7 ± 0.2 4.4 ± 0.5* 3.7 ± 0.1 4.4 ± 0.5† 0.88
AV peak gradient (mm Hg) 56 ± 4 80 ± 19* 56 ± 4 79 ± 16† 0.85
AV mean gradient (mm Hg) 32 ± 5 47 ± 14* 32 ± 4 46 ± 12† 0.76
Left Heart Dimensions
IVS (mm) 12 ± 2 12 ± 2 12 ± 2 12 ± 3 0.89
PWT (mm) 11 ± 2 12 ± 2 11 ± 1 11 ± 2 0.58
LA (mm) 36 ± 6 37 ± 7 37 ± 6 39 ± 7 0.58
LVEDD (mm) 48 ± 4 47 ± 5 50 ± 5 49 ± 6 0.86
LVESD (mm) 28 ± 5 27 ± 5 30 ± 5 30 ± 6 0.56
LV mass/BSA (g/m
2)
Men 94 ± 19 93 ± 17 94 ± 20 95 ± 11 0.54
Women 81 ± 12 82 ± 15 82 ± 11 81 ± 17 0.68
EF (%) 67 ± 7 67 ± 7 68 ± 8 69 ± 8 0.54
Conventional Diastolic Parameters
Mitral E velocity (cm/sec) 83 ± 17 83 ± 26 84 ± 26 83 ± 27 0.44
Mitral A velocity (cm/sec) 80 ± 27 80 ± 29 80 ± 27 79 ± 41 0.77
E/A ratio 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 0.75
Tissue Doppler Imaging
Lateral S’ 8.1 ± 2.7 8.1 ± 1.7 8.3 ± 1.7 8.2 ± 1.6 0.62
Lateral E’ 6.0 ± 1.2 6.1 ± 2.1 6.1 ± 2.4 6.1 ± 1.3 0.74
Lateral A’ 10.1 ± 3.1 9.4 ± 3.5 10.6 ± 3.6 10.3 ± 2.3 0.55
E/E’ (lateral) 14 ± 3 15 ± 2 14 ± 5 15 ± 4 0.77
Values are mean ± SD (percentage). y, years; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute; AVA, aortic valve
area; AV, aortic valve; IVS, interventricular septum; PWT, posterior wall thickness; LA; left atrium diameter in anterior-posterior dimension; LVEDD, left ventricular
end diastolic diameter; LVESD, left ventricular end systolic diameter; LV, left ventricular; BSA, body surface area; EF, ejection fraction; S’, systolic annular velocity;
E’, early diastolic annular velocity; A’, late diastolic annular velocity. p < 0.05* was considered significant comparing baseline and follow-up values within the
placebo arm. p < 0.05† was considered significant comparing baseline and follow-up values within the rosuvastatin arm. Overall p values are listed for the
difference of baseline and follow-up measurements comparing placebo vs. rosuvastatin, with p < 0.05‡ considered significant.
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not prevent the progression of AS in multiple rando-
mized controlled studies including ASTRONOMER,
SEAS and SALTIRE, [12,19,20] it is not unexpected that
the degree of diastolic dysfunction continued to progress
in our patient population. Following open surgical or
percutaneous aortic valve replacement, it has been
shown that diastolic parameters improve in both short
and long term follow-up [10,21,22]. It it also plausible
that our study population may have other contributing
mechanisms to progressive diastolic dysfunction includ-
ing underlying asymptomatic CAD that could affect the
subsequent outcome.
There were some important limitations in the current
study. This was an observational sub-study of the
ASTRONOMER trial. The original sample size was
intended to answer the primary question of whether sta-
tins affect the progression of mild to moderate AS,
rather than to evaluate the effects of statins on prevent-
ing diastolic dysfunction. Given the subgroup nature of
these analyses, the results of the current study need to
be interpreted cautiously. Although the ASTRONOMER
study included 272 patients in total, the current subana-
lysis study included only 168 patients in whom diastolic
echocardiographic parameters were available both at
baseline and at study end. Furthermore, the sample size
may have been too small to detect true changes even if
they exist. Similar to other studies using TDI, the metho-
dology is angle dependent and can be affected by cardiac
translation, rotation or both. Additional measurements of
diastolic function including medial TDI, LA volumes,
strain, strain rate and Vp were not available. Finally, the
baseline patients in the ASTRONOMER trial represent a
fairly homogenous, Caucasian population, and therefore,
it is difficult to extrapolate these results to other ethnic
groups.
Conclusion
In patients with mild to moderate AS, progression of
diastolic abnormalities was observed over the 3.5 year
follow-up. Rosuvastatin did not attenuate the progres-
sion of diastolic dysfunction in this patient population.
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